LINC01288: A Long Intergenic Non-Protein Coding RNA (G103689844)

Target Name: LINC01288

NCBI ID: G103689844

LINC01288

Other Name(s): long intergenic non-protein coding RNA 1288 | TCONS_00014671 | Long intergenic non-protein coding RNA 1288

LINC01288: A Long Intergenic Non-Protein Coding RNA

Introduction

LINC01288 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its ability to interact with proteins and other non-protein molecules, making it a potential drug target or biomarker.

Drug Target Potential

LINC01288 has been shown to interact with several protein targets, including the protein serine kinase PIK3CA. PIK3CA is a gene that has been linked to a variety of diseases, including cancer, diabetes, and neurodegenerative disorders. Interactions with PIK3CA have been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and angiogenesis.

In addition to its interaction with PIK3CA, LINC01288 has also been shown to interact with several other proteins, including the transcription factor ASXL1 and the protein tyrosine kinase LAT. These interactions suggest that LINC01288 may be involved in the regulation of cellular processes that are relevant to a variety of diseases.

Biomarker Potential

LINC01288 has also been shown to be expressed in a variety of tissues and cells, including cancer cells, neurons, and immune cells. This suggests that it may be a potential biomarker for cancer and other diseases. Additionally, LINC01288 has been shown to be expressed in the blood vessels of individuals with cardiovascular disease, which may make it a potential biomarker for cardiovascular disease.

Methodology

To study the potential drug target or biomarker properties of LINC01288, researchers have used a variety of techniques to analyze its function. One approach has been to use RNA sequencing (RNA-seq) to identify the expressed genes in LINC01288-rich RNA samples. This has led to the identification of several potential targets for LINC01288, including PIK3CA, ASXL1, and LAT.

Another approach has been to use a variety of biochemical assays to study the interaction of LINC01288 with its potential targets. For example, researchers have shown that LINC01288 can interact with PIK3CA and that this interaction is dose-dependent. They have also shown that LINC01288 can inhibit the activity of the protein tyrosine kinase LAT, which is involved in the regulation of cellular processes that are relevant to disease.

Conclusion

LINC01288 is a long non-coding RNA that has been identified in various organisms, including humans. It is characterized by its ability to interact with proteins and other non-protein molecules, making it a potential drug target or biomarker. The potential drug target potential of LINC01288 is suggested by its interaction with the protein serine kinase PIK3CA and several other proteins, as well as its expression in a variety of tissues and cells. The potential biomarker potential of LINC01288 is suggested by its expression in various diseases and its interaction with the transcription factor ASXL1. Further research is needed to fully understand the function of LINC01288 and its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1288

The "LINC01288 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01288 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets